Rural-Urban Differences in Dental Opioid Prescribing Among Medicaid Patients

Pharmaceuticals and Biotech Strategic Analytics, Value and Economics

Caitlin Sheetz, MPH
June 9, 2023

Previous work has found a decreasing trend in the number of opioid prescription rates in dentistry[1]. With the opioid crisis that has gripped the United States, ADVI Health wanted to explore whether important differences were found in urban and rural Medicaid populations.

Using access to the 100 percent T-MSIS Medicaid claims database, ADVI identified dentists prescribing opioids to Medicaid beneficiaries in 2020.  Beneficiaries were assigned urban or rural status based on their residential zip code.  Dentists prescribed over 8.5 million fills for opioids to over 3.5 million Medicaid beneficiaries. The average days supply was 21.5 days.

While women make up 55 percent of the Medicaid population – in both the urban and rural setting – they made up 61 percent of the beneficiaries with opioid fills.

There were no observable differences in the proportion of opioid prescriptions being prescribed by race in either urban or rural residences. However, rural Hispanic Medicaid beneficiaries were averaging a days supply of over 33 doses, which was notably higher than any other group (Figure 1). Across all other races, days supply was higher in urban Medicaid beneficiaries compared to their rural counterparts.

If you would like to know more about opioid prescribing behavior or additional Medicare or Medicaid data considerations, please get in touch to learn more.


[1] https://jada.ada.org/article/S0002-8177(21)00244-0/fulltext


Caitlin Sheetz, MPH
Senior Vice President and Head of Strategic Analytics, Value and Economics

CEO insights

Real analysis from people who’ve been there

ADVI Health Accelerates Insights with Monthly Medicare Data

ADVI Health now has access to 100% of Medicare Parts A, B, and D research files with monthly availability – …

August 12, 2026

RAND/UCLA Modified Delphi Panels

ADVI Health partners with pharmaceutical and biotech organizations to advance their evidence generation and market access strategies. We support complex research questions through primary research (e.g., …

Caitlin Sheetz, MPH
June 23, 2026

Cell and Gene Precision Medicine State Policy

The 2026 Rare Disease Reality

Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …

Marc Samuels, JD, MPH
February 26, 2026

Health Policy & Access Strategy

How HEOR and Real-World Evidence Are Reshaping Decisions in 2026

By 2026, health economics and outcomes research (HEOR) and real-world evidence (RWE) will look less like a supporting function and …

February 10, 2026

Precision Medicine

2026 Life Sciences Forecast: AI, Next-Gen Cell & Gene Therapy, and Policy Disruption

In 2026, we expect the healthcare landscape to be defined by technology breakthroughs, market access disruption, and profound policy changes. …

Marc Samuels, JD, MPH
December 16, 2025

Cell and Gene

Delivering on CAR T-cell Therapy’s Promise: Policy Solutions for the Next Era of Cancer Care

CAR T-cell therapy offers a groundbreaking treatment option for patients with relapsed or refractory hematologic malignancies, yet access remains severely …

Alicia Silver, MPP
November 21, 2025

Inflation Reduction Act

Real-World Effectiveness vs Clinical Trial Efficacy in Medicare

The Inflation Reduction Act (IRA) has ushered in a new era of drug pricing negotiations in the US. For the …

October 1, 2025

Inflation Reduction Act Pharmaceuticals and Biotech

Why is Medicare Data Central to IRA Negotiations?

The Inflation Reduction Act (IRA), passed in 2022, has transformed the way drug pricing will be managed in the United …

September 10, 2025

Reach out

Own your edge

We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.